+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Scopolamine"

From
From
Global Scopolamine Market - Product Thumbnail Image

Global Scopolamine Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Scopolamine (CAS 51-34-3) Global Market Research Report 2024 - Product Thumbnail Image

Scopolamine (CAS 51-34-3) Global Market Research Report 2024

  • Report
  • April 2024
  • 50 Pages
  • Global
From
Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
Transdermal Scopolamine: Global Strategic Business Report - Product Thumbnail Image

Transdermal Scopolamine: Global Strategic Business Report

  • Report
  • April 2024
  • 194 Pages
  • Global
From
Hyoscine Market - Growth, Trends, and Forecasts (2023 - 2028) - Product Thumbnail Image

Hyoscine Market - Growth, Trends, and Forecasts (2023 - 2028)

  • Report
  • April 2023
  • 117 Pages
  • Global
From
From
From
From
From
From
  • 16 Results (Page 1 of 1)
Loading Indicator

Scopolamine is a drug used to treat a variety of conditions related to the central nervous system. It is a muscarinic antagonist, meaning it blocks the action of the neurotransmitter acetylcholine. It is used to treat motion sickness, nausea, and vomiting, as well as to reduce the symptoms of Parkinson's disease. It is also used to treat irritable bowel syndrome and to reduce the symptoms of opioid withdrawal. Scopolamine is available in both oral and transdermal forms. Scopolamine is a widely used drug in the central nervous system drug market. It is used to treat a variety of conditions, and its availability in both oral and transdermal forms makes it a popular choice for many patients. It is also relatively inexpensive, making it an attractive option for those with limited budgets. Some companies in the scopolamine market include Novartis, Merck, Pfizer, and Mylan. Show Less Read more